




PROFICIENCY TESTING REPORT

ISHTM-AIIMS EXTERNAL QUALITY ASSURANCE PROGRAMME





Duration of stability testing - minimum upto 8 days at ambient temp. after dispatch of specimens

EQAP CODE No.: 3377 **Distribution No.:** 160-I **Month/Year:** June/2023

Instrument ID: Yumizen H550 (909YAXH02675)

Name & Contact No. of PT Co-ordinator: Dr. Seema Tyagi (Prof.), Hematology, AIIMS, Delhi,

Tel: 9013085730 , E-Mail : accuracy2000@gmail.com **Date of issue & status of the report:** 08-08-2023[Final].

CBC and Retic Assessment

				Amo	ng Lab (Aco	curacy Testin	ıg)	With	in Lab (Pre	cision Testii	ıg)
Test Parameters	S.No.	Your Result 1		Your Results Sum of 2 Value	Consensus result sum of 2 values (Assigned Value)	Uncertainty		Results	Consensus Result Diff. of 2 values (Assigned Value)	Uncertainty of Assigned Values	Z Score
WBC x10³/μl	1	3.47	2.85	6.32	12	0.089	-3.02	0.62	0.1	0.013	4.68
RBC x10 ⁶ /μl	1	4.95	4.89	9.84	9.61	0.014	0.98	0.06	0.04	0.004	0.45
Hb g/dl	1	15.3	15.2	30.5	30.3	0.054	0.22	0.1	0.1	0.011	0.00
НСТ%	1	46.2	45. <mark>2</mark>	91.4	92.3	0.320	-0.14	1	0.4	0.041	1.35
MCV-fl	1	93.3	92.5	185.8	193	0.544	-0.68	0.8	0.3	0.031	1.35
МСН-Рд	1	31.2	30.7	61.9	63	0.106	-0.56	0.5	0.3	0.023	0.90
MCHC-g/dl	1	33.8	32.8	66.6	64.6	0.229	0.45	1	0.3	0.028	2.36
Plt. x 10³/μl	1	124	119	243	305	2.716	-1.37	5	5	0.459	0.00
Retic %	2	3	2.7	5.7	5.4	0.169	0.09	0.3	0.3	0.032	0.00

P.S. Assesment

		YOUR REPORT	CONSENSUS REPORT
DLC%	3	Nrbcs=3 , Poly=10 L=8, E=0, Mono/Promono=2 , B1=19 P.M.=51, Mye=5, Meta=6, Other=Leucocytosis with Thrombocytopenia	Blast: 38-63, Poly: 9-17, Lympho: 8-20, Myelo: 2-9, Mono: 1-5, nRBC/Promyelo/Meta/Eos: 0-5
RBC Morphology	o .	Mild Anisocytosis. Normocytic Normochromic with few Microcytes.	Predominantly: Normocytic/Normochromic; Moderate: Microcytosis, Hypochromia; Mild: Anisocytosis
Diagnosis	3	AML-M3 (Acute Promyelocytic Leukemia- Microgranular/Hypogranular variant)	Acute Myeloid Leukemia (AML)

COMBINED DATA VALUES OF TOTAL PARTICIPANTS

Test parameters	C No	Total participants	Total No.	% of Lab		% of Lab		% of Lab Scor	1
rest parameters	5.NU.	current dist. 160I	responded	Among labs	Within lab	Among labs	Within lab	Among labs	Within lab
WBC x10³/μl	1	145	143	86.71	86.71	4.2	4.9	9.09	8.39
RBC x10 ⁶ /μl	1	145	145	84.14	88.97	7.59	2.07	8.27	8.96
Hb g/dl	1	145	145	85.52	86.9	6.21	6.9	8.27	6.2
HCT%	1	145	1 <mark>43</mark>	93.01	90.21	4.9	5.59	2.09	4.2
MCV-fl	1	145	143	93.71	88.11	4.2	7.69	2.09	4.2
MCH-Pg	1	145	143	87.41	93.01	5.59	2.8	7	4.19
MCHC-g/dl	1	145	143	93.71	90.21	4.2	2.8	2.09	6.99
Plt. x10³/μl	1	145	143	90.21	93.01	8.39	1.4	1.4	5.59
ReticCount%	2	145	134	92.54	95.52	5.97	0.00	1.49	4.48
PS Assessment	3	145	129	Satisfactory	:91.05%, Bo	rderline Sat	. :2.06%, Uı	nsatisfactory	:6.89%

*Comments:

- 1). Among Lab (EQA): CBC result for WBC unacceptable, may be due to random/human error
- 2). Within Lab (IQA): Difference in the CBC measurement values for WBC unacceptable, may be due to random/human error.

Note-1: EQA (External Quality Assurance): Your Performance among various of participating labs in PT, to determine the accuracy of your results.

IQA (Internal Quality Assurance): Your Performance of comparison of two consecutive measurement values within your lab to test the precision of your autoanalyzer.

Note-2: Z score among & within lab were calculated, as per to ISO/IEC 13528:2015 standard. Z score among lab (EQA)= (Your Result Sum of two values - Consensus Result sum of two values)/(Normalised IQR)

Z score within lab (IQA)= (Your Result Difference of two values - Consensus Result difference of two values)/(Normalised IQR)

 $IQR = Quartile \ 3$ - Quartile 1 of participant data, Normalised $IQR = 0.7413 \ x \ IQR$

Note-3: Z score 0 to ± 2 : Acceptable, Z score ± 2 to ± 3 : Warning Signal, Z score $> \pm 3$: Unacceptable [As per ISO/IEC 13528:2015 standard]

Note-4: Z score value between "0 to ± 2 " are texted in green colour. Z score value between " ± 2 to ± 3 " are texted in orange colour. Z score value $> \pm 3$ are texted in red colour.

Note-5: Homogeneity and stability testing of PT sample were done as per ISO 13528:2015 standard. To pass homogeneity test, between sample SD (Ss) should be smaller than the check value (0.3*SDPA). To pass the stability test, average difference in measurement values of first and last day sample $(\bar{x}-\bar{y})$ should be smaller than the check value (0.3*SDPA).

Note-6: ISHTM-AIIMS-EQAP does not subcontract any task of its scheme

Note-7: Participants are free to use methods/analyzer of their own choice.

Note-8: Proficiency testing (PT) samples are sent quarterly to each participant.

Note-9: All the necessary details regarding design and implementation of PT, are provided in the instruction sheet as well as on programme's website www.ishtmaiimseqap.com.

Note 10: Reports are kept confidential.

Report authorized by,

Dr. Seema Tyagi (Prof.)

PT Co-ordinator: ISHTM-AIIMS-EQAP

Department of Hematology, AIIMS, New Delhi

-----End Of Report-----

PT/ EQAS EVALUATION RECORD Title FRM.QCM.03 Document Number 02 Version 00 Amendment No 02.06.2023 Effective Date



09/08/23. Date of Investigation:

PT/EQAS Set Identification: 160 - I

Date of PT/EQAS

Acceptable/ Unacceptable Results

12 ± 0.08 Acceptable Result Range:

Previous Trends/ Unacceptable Results from this Analyte/ Test:

Negative Trend in WBC

Classification of Problems: (Please tick)

Clerical

Transcription error (may be pre- or post-analytical factors)

Wrong method has been registered for analysis or method change not updated.

Details of Investigation:

Methodological

Instrument function checks (e.g., temperatures, blank readings, pressures) not performed as necessary, or results not within acceptable range.

Scheduled instrument maintenance not performed appropriately.

Incorrect instrument calibration.

Standards or reagents improperly reconstituted and stored, or inadvertently used beyond expiration date. Instrument probes misaligned

Problem with instrument data processing functions. The laboratory may need to contact the manufacturer to evaluate such problems.

Problem in manufacture of reagents / standards, or with instrument settings specified by manufacturer

Carry-over from previous specimen.

Automatic pipettor not calibrated to acceptable precision and accuracy.

Imprecision from result being close to detection limit of method.

QC material not run within expiration date, or improperly stored.

	Page 1 of 4
Lupin Diagnostics (Lupin Diagnostics Limited)	CONFIDENTIAL: Authorized for internal use only
Site: All Locations	CONFIDENTIAL

Title PT/ EQAS EVALUATION RECORD

FRM.QCM.03

O2

Version 00

Amendment No 02.06.2023



QC material not run at relevant analyte concentration.

Result not within reportable range (linearity) for instrument / reagent system.

Obstruction of instrument tubing / orifice by clot or protein.

Incorrect incubation times.

Maria	4-1		- Y	See.	MARCH TO	mat	ion:
11.70	пан	155	OII.	HTV	42291	ngen i	DAPLE L

No.

Technical

EQA material improperly reconstituted.

Testing delayed after reconstitution of EQA material (with problem from evaporation or deterioration).

Sample not placed in proper order on instrument.

Result released despite unacceptable QC data.

QC data within acceptable limits but showed trend suggestive of problem with the assay.

Inappropriate quality control limits / rules. If the acceptable QC range is too wide, the probability increases that

a result will fall within the acceptable QC range yet exceed acceptable limits for EQA.

Manual pipetting / diluting performed inaccurately, at an incorrect temperature or with incorrect diluent.

Calculation error or result reported using too few significant digits.

Secondary specimen tubes incorrectly labeled.

In addition to above discipline specific errors may also occur

Details of Investigation:

No.

Problem with PT/EQAS Material

Matrix effects. The performance of some instrument / method combinations may be affected by the matrix of the PT/EQAS sample. This can be overcome to some extent by assessing participants in peer groups – to be done by the PT/EQAS provider.

Non-homogenous test material due to variability infill volumes, inadequate mixing, or inconsistent heating of lyophilized specimens.

Non-viable samples for microbiology PT/EQAS program.

Haemolysis on an immune-haemtology program samples.

Details of Investigation:

Was outer issue attended by Horiba application.

Lupin Diagnostics (Lupin Diagnostics Limited)	Page 2 of 4
Site: All Locations	CONFIDENTIAL: Authorized for internal use only

PT/ EQAS EVALUATION RECORD Titio FRM.QCM.03 **Document Number** 02 Version 00 Amendment No 02.06.2023 **Effective Date**



Specialist at Munibai. Laboratory suspected 955ve wet leads to negative bear detection is flowerformetry

Problem with PT/EQAS Evaluation

Peer group not appropriate.

Inappropriate target value: Target values developed from participant consensus can be inappropriate from non-homogeneous testing material or lingering ("masked") outliers. However, occasional inappropriate target values occur in every PT program. Inappropriate evaluation interval: An evaluation interval may be inappropriately narrow e.g. if ± 2 standard deviation units are used with an extremely precise method; the acceptable range may be much narrower than needed for clinical usefulness. Incorrect data entry by PT provider.

Detail		Epert.	CONSTRUCTOR BY	ima na T	In Par
1-30010011	56 (C) E	BEIN	resar	плен	10.01

No.

No Explanation: Attributed to Random Error

Any Others (explain)

Summary of Investigation:

Is c performace within a range other parameter performance in Egas found satisfactory

Was patient data affected? & Corrective action taken if Patient data was affected.

No.

Corrective/ Preventive action taken to prevent Reoccurrence

As part of preventile action was parlameter performance verify by stability study in mumbai.

Lupin Diagnostics (Lupin Diagnostics Limited)	Page 3 of 4
Site: All Locations	CONFIDENTIAL: Authorized for internal use only

Title	PT/ EQAS EVALUATION RECORD
Document Number	FRM.QCM.03
Version	02
Amendment No	00
Effective Date	02.06.2023



Conclusions

WiBC parlameta negative bras due to method of detection.

Quality Manager/ Team Leader

Date: 09/08/2023

Lab Head

09/08/2023

	Page 4 of 4
Lupin Diagnostics (Lupin Diagnostics Limited)	CONFIDENTIAL: Authorized for internal use only
Site: All Locations	



Inter laboratory comparison study report of Complete Blood count Lupin Diagnostics, SL Andheri

Reference Laboratory- Lupin Diagnostics , NRL Date of study conducted- 01.02.2023 Study performed for – WBC Negative shift

								7	San	Sample-1							
رن رن	Parameters		24 Hrs			48 hrs			96hrs			120hrs			144 hrs		Reference
2		NRL	Andheri	%Diff	NRL	Andheri	%Diff	NRL	Andheri	%Diff	NRL	Andheri	%Diff	NRL	Andheri	%Diff	range
-	RBC	4.75	4.62	2.81	4.66	4.69	-0.64	4.62	4.66	98.0-	4.71	4.66	1.07	4.76	4.63	2.81	3.8-6
1 0	HB	13.00	12.70	2.36	12.60	12.70	-0.79	12.70	12.80	-0.78	13.00	12.60	3.17	13.00	12.90	0.78	11.5-17
1 6	PCV	38.60	39.50	-2.28	39.60	40.20	-1.49	39.50	39.70	-0.50	38.40	39.60	-3.03	38.60	39.60	-2.53	35-52
4	MCV	81.20	85.50	-5.03	85.10	85.60	-0.58	85.50	85.20	0.35	81.40	85.10	-4.35	81.00	85.40	-5.15	76-100
	王	27.40	27.40	0.00	27.00	27.10	-0.37	27.40	27.50	-0.36	27.70	27.00	2.59	27.30	27.90	-2.15	27-34
9	HCHC	33.70	32.00	5.31	31.70	31.60	0.32	32.00	32.30	-0.93	34.00	31.70	7.26	33.70	32.60	3.37	32-35
, _	RDWCV	14.50	14.80	-2.03	15.00	15.40	-2.60	14.80	15.10	-1.99	15.60	15.00	4.00	15.30	15.50	-1.29	11.0-17
. 00	RDWSD	46.20	48.70	-5.13	49.60	50.40	-1.59	48.70	49.60	-1.81	30.20	49.60	-39.11	47.90	50.40	-4.96	37-49
0	PLT	274.00	259.00	5.79	262.00	252.00	3.97	259.00	266.00	-2.63	302.00	262.00	15.27	290.00	267.00	8.61	150-400
9	PCT	0.27	0.26	3.85	0.30	0.26	15.38	0.26	0.29	-10.34	0.32	0.30	6.67	0.33	0.31	6.45	0.15-0.40
=	MPV	9.90	10.10	-1.98	11.40	10.30	10.68	10.10	10.90	-7.34	10.70	11.40	-6.14	11.20	11.60	-3.45	8.0-11
12	PDW	19.00	17.50	8.57	20.50	16.90	21.30	17.50	17.80	-1.69	20.00	20.50	-2.44	20.30	21.60	-6.02	11.0-22
1,2	PLCC	100.00	90.00	11.11	112.00	92.00	21.74	90.06	106.00	-15.09	130.00	112.00	16.07	133.00	122.00	9.05	44-140
141	PLCR	36.70	-	5.46	42.90	36.40	17.86	34.80	39.80	-12.56	43.00	42.90	0.23	45.90	45.70	0.44	18-50
15	WBC	12.35	12.88	-4.11	11.38	12.44	-8.52	12.88	12.39	3.95	12.13	11.38	6.59	10.30	9.53	8.08	3.5-10
19	NEUT	8.70	8.85	-1.69	7.01	8.63	-18.77	8.85	8.47	4.49	8.60	7.01	22.68	6.59	6.27	5.10	1.6-7
17	LYMP	2.70	2.76	-2.17	3.42	2.72	25.74	2.76	2.93	-5.80	2.59	3.42	-24.27	2.83	2.25	25.78	1.0-3
18	MONO	0.54	0.74	27.03	0.45	0.63	-28.57	0.74	0.50	48.00	0.45	0.45	0.00	0.41	0.57	-28.07	0.2-0.8
19	EOS	0.24	0.34	29.41	0.29	0.27	7.41	0.34	0.28	21.43	0.25	0.29	-13.79	0.29	0.32	-9.38	0.0-0.50
20	BASO	0.04	0.07	42.86	0.10	0.07	42.86	0.07	0.09	-22.22	0.03	0.10	-70.00	0.05	90.0	-16.67	0.0-0.15
21	CIC	0.06	0.12	50.00	0.11	0.12	-8.33	0.12	0.12	0.00	0.21	0.11	90.91	0.13	90.0	116.67	0.0-0.10
22	NEUT%	70.60	69.40	1.73	62.10	70.00	-11.29	69.40	69.10	0.43	72.10	62.10	16.10	64.90	66.10	-1.82	40-73
23	LYM%	22.60	21.60	4.63	30.40	22.10	37.56	21.60	23.90	-9.62	21.70	30.40	-28.62	27.80	23.80	16.81	15-45
24	%ONOW	4.40	5.80	24.14	4.00	5.10	-21.57	5.80	4.00	45.00	3.80	4.00	-5.00	4.00	6.10	-34.43	4.0-12



j	Lunin Diagnostics	S. S. Andheri	heri										-1111	PIPIN			
Inter	Inter laboratory comparison study report of Complete Blood count	omparis	on study	report o	of Comple	ete Blood	count						_	Sood	Good health starts here	ts here	
-						-		-		-		6	6	0	6	1	r L
25	EOS%	2.00	2.70	25.93	2.60	2.20	18.18	2.70	2.30	17.39	2.10	2.60	-19.23	2.80	3.40	-1/.65	0.5-7
56	BASO%	0.40	0.50	20.00	0.90	09.0	50.00	0.50	0.70	-28.57	0.30	06:0	-66.67	0.50	09:0	-16.67	0.0-2.0
1									200	Samula.2							
Ş,			24 Um			48 hrs	1		96hrs	mpile 2		120hrs			144hrs		Reference
2	rarameters	NRI	Andheri	%Diff	NRL	Andheri	%Diff	NRL	Andheri	%Diff	NRL	Andheri	%Diff	NRL	Andheri	%Diff	range
-	RBC	5.47	5.35	2.24	5.33	5.38	-0.93	5:35	5.31	0.75	5.43	5.33	1.88	5.45	5.30	2.83	3.8-6
1 ~	HB	14.60	14.30	2.10	14.00	14.30	-2.10	14.30	14.20	0.70	14.50	14.00	3.57	14.40	14.40	0.00	11.5-17
1 6	PC	43.50	45.00	-3.33	44.50	45.00	-1.11	45.00	44.40	1.35	43.00	44.50	-3.37	43.20	44.60	-3.14	35-52
4	MCV	79.50	84.10	-5.47	83.40	83.60	-0.24	84.10	83.60	09.0	79.20	83.40	-5.04	79.30	84.10	-5.71	76-100
- L	HCH	26.70	26.70	00.00	26.30	26.60	-1.13	26.70	26.80	-0.37	26.70	26.30	1.52	26.50	27.10	-2.21	27-34
9	HCHC	33.60	31.70	5.99	31.60	31.80	-0.63	31.70	32.00	-0.94	33.70	31.60	6.65	33.40	32.20	3.73	32-35
1	RDWCV	14.40	14.70	-2.04	14.90	14.20	4.93	14.70	14.60	0.68	15.00	14.90	0.67	15.00	15.30	-1.96	11.0-17
. 00	RDWSD	45.40	47.90	-5.22	47.90	47.00	1.91	47.90	47.90	00.00	46.20	47.90	-3.55	15.00	49.60	92.69-	37-49
6	PLT	248.00	202.00	22.77	216.00	211.00	2.37	202.00	204.00	-0.98	228.00	216.00	5.56	212.00	208.00	1.92	150-400
9	PCT	0.32	0.26	23.08	0.30	0.27	11.11	0.26	0.25	4.00	0.30	0.30	0.00	0.29	0.28	3.57	0.15-0.40
=	MPV	13.00	12.70	2.36	13.70	12.60	8.73	12.70	12.50	1.60	13.10	13.70	-4.38	13.60	13.40	1.49	8.0-11
1 2	MOA	27.60	24.30	13.58	27.20	23.50	15.74	24.30	23.90	1.67	27.90	27.20	2.57	27.20	26.00	4.62	11.0-22
1 2	PLCC	138.00	112.00	23.21	130.00	113.00	15.04	112.00	106.00	99'5	133.00	130.00	2.31	129.00	121.00	6.61	44-140
4	PLCR	55.90	55.50	0.72	60.10	53.30	12.76	55.50	52.20	6.32	58.40	60.10	-2.83	60.80	58.00	4.83	18-50
13	WBC	6.21	6.14	1.14	5.15	6.14	-16.12	6.14	6.12	0.33	5.68	5.15	10.29	4.09	4.32	-5.32	3.5-10
16	NEUT	3.52	3.28	7.32	2.51	3.48	-27.87	3.28	3.34	-1.80	3.13	2.51	24.70	1.43	1.69	-15.38	1.6-7
17	LYMP	2.16	2.16	0.00	2.05	1.99	3.02	2.16	2.14	0.93	2.03	2.05	-0.98	2.16	2.18	-0.92	1.0-3
18	MONO	0.36	0.41	12.20	0.33	0.37	-10.81	0.41	0.38	7.89	0.33	0.33	00.00	0.27	0.22	22.73	0.2-0.8
19	EOS	0.13	0.13	0.00	0.16	0.16	00.00	0.13	0.16	-18.75	0.11	0.16	-31.25	0.13	0.12	8.33	0.0-0.50
20	BASO	0.03	0.04	25.00	0.09	0.04	125.00	0.04	0.07	-42.86	0.04	60:0	-55.56	0.05	0.09	-44.44	0.0-0.15
21	TIC	0.01	0.12	91.67	0.01	60.0	-88.89	0.12	0.03	300.00	0.04	0.01	300.00	0.05	0.02	150.00	0.0-0.10
22	NEUT%	57.10	54.70	4.39	49.00	57.20	-14.34	54.70	54.90	-0.36	55.60	49.00	13.47	35.30	39.40	-10.41	40-73
23	TAM%	34.80	35.80	-2.79	39.90	32.80	21.65	35.80	35.20	1.70	36.00	39.90	-9.77	53.50	50.70	5.52	15-45



Lubi	Lupin Diagnostics . SL Andheri	s. SL And	heri										1	MIN	-	0	
Inte	Inter laboratory comparison study report of Complete Blood count	comparis	on study	report	of Comple	ete Blood	count							Good	health star	ts here	
											-		-				-
24	%ONOW	5.70	6.70	14.93	6.30	6.10	3.28	6.70	6.20	90.8	5.80	6.30	-7.94	6.80	5.00	36.00	4.0-12
75	FO5%	2.00	2.10	2.10 -4.76	3.00	2.70	11.11	2.10	2.60	-19.23	1.90	3.00	-36.67	3.20	2.70	18.52	0.5-7
56	BASO%	0.40	0.70	42.86	1.80	1.20	20.00	0.70	1.10	-36.36	0.70	1.80	-61.11	1.20	2.20	-45.45	0.0-2.0

Approved by (Dr Sagar)

Conclusion:

WBC negative shift noted with increasing in time interval High % Difference noted due to statistical limitations. >80% Clinical correlation noted in both samples.


Observations-

Based on obtained result recovery Inter Iaboratory comparison study successfully passed for CBC test parameter.



Day-1





Silde Review

eutrophil	Myeloblast	Anisocytosis
ymphocyte onocyte oslnophii asophii	Promyelocyte Myelocyte Metamyelocyte Blast	Hypochromia Polychromasia Polkllocytosis
ypical Lymphocyte ther	Target Cell Sickle Cell	Microcytosis Macrocytosis Platelet Clumps
viewed on	by	Signature :

28/2023 03:48:28 PM

Printed by : LUPIN

S/N106YAXH03393



Results Run Date 02/28/2023 03:44:49 PM Operator LUPIN Last Name Sample ID PS VALIDATION First Name Rack/Pos Gender Age Department Patient ID Physician Birth Date Type Standard Sample comments Range RBC Recommended actions 4.72 10º/µL 3.80 - 6.00 Slide review 12.7 HGB g/dL 11.5 - 17.0 Alarms HCT 40.5 % 35.0 - 52.0 Control failed MCV 85.9 WBC µm³ 76.0 - 100.0 MON Interference MCH 26.9 27.0 - 34.0 pg Susp. Pathologies MCHC 31.4 g/dL 32.0 - 35.0 Leukocytosis RDW-CV Neutrophilia 15.0 % 11.0 - 17.0 RDW-SD 49.6 h µm³ 37.0 - 49.0 150 150 Range PLT 281 103/µL 150 - 400 PLT 0.29 PCT % 0.15 - 0.40 MPV 10.4 µm³ 8.0 - 11.0 PDW 17.6 µm³ 11.0 - 22.0 P-LCC 104 103/µL 44 - 140 37.0 P-LCR % 18.0 - 50.0 20 Range 13.16 DIF WBC 3.50 - 10.00 103/µL Range 19/2 Range 1.60 - 7.00 NEU 9.17 69.9 40.0 - 73.0 LYM 2.94 1.00 - 3.00 22.4 15.0 - 45.0 MON 0.60 * 0.20 - 0.804.6 4.0 - 12.0 0.28 EOS 0.00 - 0.50 2.2 0.5 - 7.0 BAS 0.12 0.00 - 0.15 0.9 0.0 - 2.00.05 LIC 0.00 - 0.10

Slide Review

0.0 - 1.0

0.4

	Printed by : LUPIN	S/N 106YAXH03393
8/2023 03:46:31 PM		
		Signature:
fewed on	by s. The life of	그리는 사람들이 살아내는 그 그림을 하는 것 같습니다.
	Sickle Cell	Platelet Clumps
ier	Target Cell	Macrocytosis
rpical Lymphocyte	Blast	Microcytosis
sophil	Metamyelocyte	Polkilocytosis
sinophil	Myelocyte	Polychromasia
inocyte		Hypechromia
mphocyte	Promyelocyte	Anisocytosis
utrophil	Myeloblast	



			Tara	Res	ults	3.000	
	Run Da	te 03/01/202	3 03:59:32 PM		•	perator LUPIN	
	Last Nam			•	1 11 11 11 11		
	First Nam	ie			Sai	nple ID PS VALID	DAY-2
	Gende	er	Age			ick/Pos	Ne ¹
	Patient I	D				rtment	
	Birth Dat	е			Pn	ysiclan Type Standard	
	Sampl comment	e 5			**:	-3P- Danidald	
			Range				August 10 September 1 1 T
RBC		106/µL	3.80 - 6.0	0		= '	Alarms
HGB		g/dL	11.5 - 17.				Control failed Susp. Pathologies
HCT	39.5	%	35.0 - 52.0		Τ Λ	5-41	Neutrophilia
MCV		μm³	76.0 - 100.		1 /\	RBC	
MCH	27.4	pg	27.0 - 34.0	-	1 /1		
MCHC		g/dL	32.0 - 35.0		1 / \		
DW-CV		%	11.0 - 17.0		11		
DW-SD	48.7	μm³	37.0 - 49.0		50 100	158	
PLT	259	10³/μL	Range				
PCT	0.26	%	150 - 400			: PLT	
MPV	10.1	μm³	0.15 - 0.40				gan e la la la gara de la sulta de la s La calegacia de la sulta d
PDW	17.5	µm³	8.0 - 11.0				
P-LCC	90	10³/µL	11.0 - 22.0		11/1		
P-LCR	34.8	%	44 - 140			`	
ল কাক		, , , , , ,	18.0 - 50.0		2 10	20 20	
Carrens.			Range		1		
WBC	12.88 h	103/µL	3.50 - 10.00			DIF	
	#	Range	%	-			
NEU	8.85 H	1.60 - 7.00		Range			
LYM	2.76	1.00 - 3.00		40.0 - 73.0			
MON	0.74	0.20 - 0.80		15.0 - 45.0			
EOS	0.34	0.00 - 0.50	2.7	4.0 - 12.0	334.00		
BAS	0.07	0.00 - 0.15	0.5	0.5 - 7.0			
LIC	0.12 h	0.00 - 0.10	0.9	0.0 - 2.0	100		
		0:40	0.9	0.0 - 1.0			

Silde Review

AATITOTO GATOTIOD LIM	Printed by : LUPIN	S/N TORYAYHORRO
1/01/2023 04:01:36 PM		
eviewed on	by Sign	nature :
Other	Sickle Cell	Macrocytosis Platelet Clumps
Atypical Lymphocyte	Blast Target Cell	Microcytosis
Basophil	Metamyelocyte	Polkilocytosis
Monocyte Eosinophil	Myelocyte	Polychromasia
Lymphocyte	Promyelocyte	Anisocytosis Hypochromia
Neutrophil	Myeloblast	



	_				Results			
	Run	Date	03/01/2023	04:02:26 PM		Operator	LIPIN	
	Last							
	First	Name				Sample ID	DH VALI	DAY-2
		ender		Age		Rack/Pos		
	Patie	ent ID				Department Physician		
	Birth	Date					Standard	
	Sa comm	mple lents			•			
	,			Prison.				
RBC	5.35	*	10°/µL	Range 3.80 - 6.00				Recommended actions
HGB	14.3		g/dL	11.5 - 17.0				Slide review
НСТ	45.0	*	%	35.0 - 52.0		4	3	Alarms Control failed
MCV	84.1	*	μm³	76.0 - 100.0		Λ	RBC	PLT
мсн	26.7	I	pg	27.0 - 34.0				RBC PLT Interference
MCHC	31.7	L	g/dL	32.0 - 35.0		1		Susp. Pathologies Macroplatelets
DW-CV	14.7	****	%	11.0 - 17.0	1 1	1		aciobiatalets
DW-SD	47.9		μm³	37.0 - 49.0	1			
			berri		56	189 156		
PLT	202	*	10³/µL	Range 150 - 400	9.00			
PCT	0.26	*	%	0.15 - 0.40		t∦ galair	ALT	
MPV	12.7	H*		8.0 - 11.0				
PDW	24.3	h*	μm³.	11.0 - 22.0	- Hanne 1		•	
P-LCC	112	• • • •	10³/µL	44 - 140	11/	4		
P-LCR	55.5	h	%	18.0 - 50.0	علها	\perp		
				10.0 - 50.0		10 20	39	
				Range				
WBC	6.14		103/UL	3.50 - 10.00			DIF	
			,		. 4			
	#		Range	% Ra	nge			
NEU	3.28		1.60 - 7.00		- 73.0 .		30g	
LYM	2.16	-	1.00 - 3.00		- 45.0		****	
MON	0.41		0.20 - 0.80		12.0			
EOS	0.13	-	0.00 - 0.50		7.0			
BAS	0.04		0.00 - 0.15		2.0		, -	
LIC	0.12	h	0.00 - 0.10		1.0		341	
			* •	P. R. S. SANS	4,150		-	

Silde Review

3/01/2023 04:03:55 PM	Printed by : LUPIN	5/N 106YAXH03393 1
- 4	bys	ilgnature :
Reviewed on		Platelet Clumps
Other	Sickie Cell	Macrocytosis
Atypical Lymphocyte	Target Cell	Microcytosis
Basophil	Blast	Polkilocytosis
Eosinophil	Myelocyte Metamyelocyte	Polychromasia
Monocyte	Promyelocyte	Hypochromia
Lymphocyte		Anisocytosis
Neutrophil	Myeloblast	



DAY-3

,_ueg 43				Printe	ed by : LUPIN		5/N 106YAXH03393	
/2023 va	:56:37 PM							
ewed on				by		Signature :		
				Sickle Cell		Plate	let Clumps	
er	······································			Target Cell		Macr	ocytosis	
ical Lym	nhocyte		1	Blast		Micro	ocytosis	
phil	;			Metamyelocyte			locytosis	
nophil				Myelocyte		and the second of the second o	chromasia	
ocyte				Promyelocyte	444	Нурс	chromia	afilijelika i st. Lilijelijaji se ili selika tetori i s
phocyte							ocytosis	
trophil				Myeloblast				
				SI	lide Review			
			jak.					
	~ :		0.10	T.O 0.0	0-1.0			
LIC	0.12 h		0.00 - 0.15 0.00 - 0.10		0-2.0	(B) (C)		
EOS BAS	0.27 0.07		0.00 - 0.50		5 - 7.0			
MON	0.63		0.20 - 0.80		0 - 12.0			
LYM	2.72		1.00 - 3.00	22.1 15.	0 - 45.0			
NEU	8.63 H		L.60 - 7.00	70.0 40.	0 - 73.0			
	#		Range		ange			
٠.						W.		
WBC	12.44 h	1	10³/µL 3	Range .50 - 10.00		22	DIF	
P-LCR	36.4		%	18.0 - 50.0		10 20	26	
P-LCC	92		10³/µL	44 - 140				
PDW	16.9		μm³	11.0 - 22.0	1/	\checkmark		
MPV	10.3		μm_3	8.0 - 11.0				
PCT	0.26		%	0.15 - 0.40				
PLT	252		103/µL	150 - 400	11		; PLT	
- 18				Range		124 150		
DW-SD	50.4	h	µm³	37.0 - 49.0	50	158 150		
DW-CV	15.4		%	11.0 - 17.0				
MCHC	31.6	L	g/dL	32.0 - 35.0			orani kalendari Nama Salamatan Kalendari	inger Samme in the second second
MCH	27.1		pg	27.0 - 34.0		1		
MCV		*	μm³	76.0 - 100.0			FIBC	
нст	40.2	*	%	35.0 - 52.0	1	۸	Neutrophill	a a
HGB	12.7		g/dL	11.5 - 17.0			Control fail Susp. Pati	ed
RBC	4.69	*	106/μL	Range 3.80 - 6.00			Alarms	
	Sam Commer							
						Туре	Standard	
	Birth Da					Physician		
	Patient			790		Department		
	Gen	der		Age		Rack/Pos		
	First Na				•	Sample ID	PRIYA.VALID	
	AND THE REAL PROPERTY.	4111						
	Last Na			03:55:10 PM		Operator	LUPIN	



1

DAW-3

Results Run Date 03/02/2023 03:57:09 PM Operator LUPIN Last Name Sample ID DANISH, VALID First Name Rack/Pos Gender Age Department Patient ID Physician Birth Date Type Standard Sample comments Range Recommended actions RBC 5.38 10%/UL 3.80 - 6.00 Slide review HGB 14.3 g/dL 11.5 - 17.0 Alarms HCT 45.0 % Control falled 35.0 - 52.0 MCV 83.6 WBC um³ 76.0 - 100.0 LYM Interference 26.6 MCH pg 27.0 - 34.0 PLT MCHC 31.8 g/dL **RBC PLT Interference** 32.0 - 35.0 Susp. Pathologies RDW-CV 14.2 % 11.0 - 17.0 Macroplatelets RDW-SD 47.0 µm³ 37.0 - 49.0 159 PLT aggregate or NRBC? Range PLT 211 103/HL 150 - 400 0.27 PCT % 0.15 - 0.40 MPV 12.6 H* µm³ 8.0 - 11.0 PDW 23.5 h* µm³ 11.0 - 22.0 113 P-LCC 103/uL 44 - 140 P-LCR 53,3 h % 18.0 - 50.0 Range DIF WBC 6.16 103/µL 3.50 - 10.00 # Range % Range NEU 3.48 1.60 - 7.00 57.2 40.0 - 73.0 LYM 1.99 1.00 - 3.00 32.8 15.0 - 45.0 MON 0.37 0.20 - 0.806.1 4.0 - 12.0 EOS 0.16 0.00 - 0.50 2.7 0.5 - 7.00.07 0.00 - 0.15 BAS * 1.2 0.0 - 2.0 0.09 LIC 0.00 - 0.10 1.4 0.0 - 1.0

Slide Review

1/2023 04:02:06 PM	Printed by : LUPIN	5/N 106YAXH03393
ewed on	by	jnature :
	Sickle Cell	Platelet Clumps
pical Lymphocyte er	Target Cell	Macrocytosis
ophil	Blast	Microcytosis
inophii	Metamyelocyte	Poikilocytosis
nocyte	Myelocyte	Polychromasia
nphocyte	Promyelocyte	Hypochromia
utrophil	Myeloblast	Anisocytosis



					Resul	lts		The Paris of Lands
	Run	Date	03/03/202	3 03:52:10 PM		Operator	Lithiat	
	Last	Name						
	First	Name	k ti s di			Sample ID		DAY-4
		ander		Age		Rack/Pos		
	Patie	nt ID				Department Physician		
	Birth	Date					Standard	
:	Sa comn	mple ents						
				Range		В.		Watinday Louis
RBC	4.66		106/µL	3.80 - 6.00				Recommended actions Slide review
HGB	12.8		g/dL	11.5 - 17.0				Alarms
HCT	39.7		%	35.0 - 52.0		1 Λ	RBC	Control failed
MCV	85.2		µm³	76.0 - 100.0		1 /1	ROU	Susp. Pathologies PLT aggregate ?
MCH	27.5		pg	27.0 - 34.0		1 / 1		Neutrophilia
MCHC	32.3		g/dL	32.0 - 35.0		1 + 1 + 1		
DW-CV	15.1		%	11.0 - 17.0				
DW-SD	49.6	h	μm³	37.0 - 49.0		50 180 168		
	200			Range				
PLT	266	*	10 ³ /μL	150 - 400		11 1	: PLT	
PCT	0.29	*	%	0.15 - 0.40				
MPV	10.9	ж	µm³	8.0 - 11.0				
PDW	17.8	*	μm³	11.0 - 22.0				
P-LCC	106		10³/µL	44 - 140		<i>y</i> 1×.		
P-LCR	39.8		%	18.0 - 50.0		2 10 20	38	
1000	40 00			Range	1	- A Programme	DIF	
WBC	12.39	n	10³/µL	3.50 - 10.00				
	#		Range	%	. 1			
NEU	8.47	н	1.60 - 7.00		lange .0 - 73.0			ander Victoria de la composition de la compo
LYM	2.93	**	1,00 - 3.00			and the state of t		
MON	0.50		0.20 - 0.80		.0 - 45.0			
EOS	0.28		0.00 - 0.50		0 - 12.0			
	0.09		0.00 - 0.15		5 - 7.0			
LIC	0.12	h	0.00 - 0.10		0 - 2.0			
	To a set office	* 3	2.00 - 0.10	1.0 0.	0-1.0	i lasia		

Slide Review

-9/99/2023 U3:33:34 PM	Printed by : LU	PIN \$/N106YAXH03393
-3/03/2023 03:53:54 PM		
Reviewed on	by	Signature :
-0.43	Sickle Cell	Platelet Clumps
Atypical Lymphocyte Other	Target Cell	Macrocytosis
Basophil	Blast	Polkliocytosis Microcytosis
Eosinophii	Metamyelocyte	Polychromasia
Monocyte	Promyelocyte Myelocyte	Hypochromia
Lymphocyte	Myeloblast	Anisocytosis



					Resu	its			
	Run	Date	03/03/2023	03:54:41 PM					
	Last					Operato			
	First	Vame				Sample II	DH VALL	DAY-4	1
		ender		Age		Rack/Pos			
	Patie	nt ID				Department Physician			
	Birth	Date					Standard		
	Sa	mple ents							
RBC	5.31			Range				Bassas	
HGB	14.2		10°/µL	3.80 - 6.00				Recommended Slide review	actions
HCT	44.4		g/dL %	11.5 - 17.0				Alarms	
	83.6		µm³	35.0 - 52.0		1 Λ	RBC	Control failed WBC	
MCH	26.8	1	pg	76.0 - 100.0	The second second second	A		LYM Interference	
MCHC	32.0		g/dL	27.0 - 34.0 32.0 - 35.0				PLT	
	14.6		%	11.0 - 17.0		1 + 1 + 1		RBC PLT Interferi Susp. Patholog	ence les
RDW-SD	47.9		μm³	37.0 - 49.0				Macroplatelets	
				Range		55 188 156		PLT aggregate or	NRBC ?
PLT	204	*	10³/μL	150 - 400					
PCT	0.25	*	%	0.15 - 0.40			PLT		
	12.5	H×	hw ₃	8.0 - 11.0	Agency (Alberta)				
	23.9	h*	μm³	11.0 - 22.0					
	106		10³/µL	44 - 140				to a second of the second of	
P-LCR	52.2	h	%	18.0 - 50.0		2 10 20	30		
WBC 6	5.12		*****	Range			DIF		
WAC (J. 1.Z	ж	10°/µL 3	3.50 - 10.00			•		
e i	#		Range	%					
NEU 3	3.34	*	1.60 - 7.00		Range				
LYM 2	.14	*	1.00 - 3.00	the second secon	40.0 - 73.0 15.0 - 45.0				
MON 0	.38	*	0.20 - 0.80	6.2 *	4.0 - 12.0			and the metapholic completes and the complete of the complete	
EOS 0	.16	*	0.00 - 0.50	2.6 *	0.5 - 7.0			电量控制 化氯	
BAS 0	.07	*	0.00 - 0.15	1.1 *	0.0 - 2.0	19		Jerdan J	
LIC 0	.03	*	0.00 - 0.10	0.5 *	0.0 - 1.0				
			** .						
					Slide Revie	w .			
# 2 5 m				L. L. Carr	n magin adire				
leutrophil				Myeloblast		Anie	ocytosis		
ymphocyte				Promyelocyt	V.	1000	ochromia		# 4.11
lonocyte		-		Myelocyte			chromasia		
osinophil				Metamyelocy	te				
asophil				Blast		and the first than the first terms of the first ter	locytosis		
typical Lymph	ocyte			Target Cell		and the second s	cytosis		
ther				Sickle Cell			ocytosis		
2636				TOTAL THE SHOWERS	: :::	Plate	let Clumps		
eviewed on				by		Signature :			
· · · · · · · · · · · · · · · · · · ·									



		-						1. 1		
	· D vom	Phylips			Res	ults			38.7.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.	
				3 04:00:46 PM			Operator LUPIN			
	Last						ample ID PS VAI	LDAY 6		
		vame inder		<u> </u>			tack/Pos	1 DAY-5	ing the second s	
	Patie			Age		Dep	artment			
	Birth	Date				P	hysician			
		mple					Type Standa	rd.		
				Range						
RBC	4.66	*	10°/µL	3.80 - 6.00				Recomm	anded action	5
HGB	12.6		g/dL	11.5 - 17.0				Slide revi Alarms	ew .	
HCT	39.6	*	%	35.0 - 52.0		1 ^	4	Control fa	iled	
MCV	85.1	*	μm³	76.0 - 100.0		1 /	R6	WBC		
MCH	27.0	1	pg	27.0 - 34.0		$I = I \Lambda$		LYM Inter	erence	
MCHC	31.7	L	g/dL	32.0 - 35.0		1 / 1		Susp. Pat	nologies gate or NRBC	
RDW-CV	15.0		%	11.0 - 17.0		1 / \			agre of MVBC	Maria de la companya
RDW-SD	49.5	h	μm³	37.0 - 49.0		L-/,				
				Range		50 169	159			
PLT	262	*	10³/µL	150 - 400		e# 340 G€:				
PCT	0.30	*	%	0.15 - 0.40			;PL			
MPV	11.4	h*	µm³	The state of the s						
PDW	20.5	*	μm³	8.0 - 11.0						
P-LCC	112	3	10³/µL	11.0 - 22.0		$\square \wedge$				
P-LCR	42.9		100	44 - 140						
	76.3		%	18.0 - 50.0		2 10	20 30			
			.:	Range						
WBC	11.38	h*	103/11	3.50 - 10.00		***	BIF			
	#		Range	%						
NEU	7.01	h*	1.60 - 7.00		Range		A STORY			
LYM	3.42		1.00 - 3.00		40.0 - 73.0					
	0.45		0.20 - 0.80	P. P. S.	15.0 - 45.0					
	0.29		0.00 - 0.50	LEO TO	4.0 - 12.0					
	0.10		0.00 - 0. <u>1</u> 5		0.5 - 7.0		3			
				0.0	0.0 - 2.0	1.37				
LIC	V. i. i.	h ∗ ⊲	0.00 - 0.10	1.0 *	0.0 - 1.0		iet.			
					Silde Revi	BW.	je s Raja nije sa jila sana			
an a demand of the last										
eutrophil				Myeloblast		iedie III.	Anisocytosis			
mphocyte				Promyelocyte				the fact that the second of the		
onocyte				Myelocyte			Hypochromia			
osinophil				Metamyelocy			Polychromas			
sophii					ue	Tani Mila	Polkllocytosi	5		
ypical Lymp	hocute			Blast		pakan ali P	Microcytosis			
her	ye			Target Cell			Macrocytosis			
ea c⊕t				Sickle Cell			Platelet Clum	that the same and the		
viewed on _	n inc _ uses	302		_by						
				- Yy		Signal	ture :			
OADASS S	MN									
04/2023 04:	02:25 PI	4		Pr	inted by : LI	JPIN	S/N 10	6YAXH03393		-



				44	Resu	its		
	Run	Date	03/04/2023	04:02:58 PM				
	Last First G	Name Name ende:				Samı	erator LUPIN ple ID DS VALI k/Pos	DAY-5
	Patie			Age		Depart		
	Birth						lcian	**. : : * <u>.</u>
	1.11						Type Standard	
	comm	mple						
RBC	5.33	*	10°/μL	Range				Recommended actions
HGB		7	g/dL	3.80 - 6.00				Slide review
нст		*	%	11.5 - 17.0				Alarms
MCV		*		35.0 - 52.0	_	Ι Λ	RBC	Control failed WBC
MCH	26.3	1		76.0 - 100.0		1 /\		LYM Interference
MCHC	31.6		pg g/dL	27.0 - 34.0		$I = I \Lambda$		PLT
RDW-CV	14.9		9/UL %	32.0 - 35.0		1 / /		RBC PLT interference Susp. Pathologies
RDW-SD	47.9		hw ₃	11.0 - 17.0		oxdot oxdot		Macroplatelets
			patr	37.0 - 49.0		56 159 1	59	PLT aggregate or NRBC 7
PLT	216	*	10³/µL	Range				
PCT	0.30	*	%	150 - 400			PLT	
MPV	13.7	H×		0.15 - 0.40 8.0 - 11.0				
PDW	27.2	H*	µm³					
P-LCC	130	* * *	10³/µL	11.0 - 22.0 44 - 140		1124		
P-LCR	60.1	h	%	18.0 - 50.0				
	_	***	79	10.0 - 30.0		2 10	20 30	
				Range				
WBC	5.15	*	103/µL	3.50 - 10.00			DIF	
				10.00		V.		
- 2	#		Range	%	Danne 1			
NEU	2.51	*	1.60 - 7.00		Range 1.0 - 73.0		12.	
LYM	2.05	*	1.00 - 3.00		.0 - 45.0			
MON	0.33	*	0.20 - 0.80		0 - 12.0			
EOS	0.16	*	0.00 - 0.50		.5 - 7.0			
BAS	0.09	*	0.00 - 0.15		.0 - 2.0		Y	
LIC	0.01	*	0.00 - 0.10	4.4	.0-2.0		** 1 m 1 m 1 m 1 m 1 m 1 m 1 m 1 m 1 m 1	
			THE STATE OF THE S		4 - 4.0 L			
	3							
				a a casa 1.1 asa 1.1	ilide Revie			
eutrophil				Myeloblast				
mphocyte				*		1. 1.	Anisocytosis	

Neutrophil Lymphocyte Monocyte Eosinophil Basophil Atypical Lymphocyte Other	Myeloblast Promyelocyte Myelocyte Metamyelocyte Blast Target Cell Sickle Cell	Anisocytosis Hypochromia Polychromasia Polkilocytosis Microcytosis Macrocytosis
Reviewed on		Platelet Clumps Ignature :

13/04/2023 04:04:29 PM

Printed by : LUPIN

S/N 106YAXH03393



H. 1111	Div				sults		
			03/05/2023	04:07:10 PM	Operato	r LUPIN	
	Läst Name First Name Gender Patient ID				Sample ID		niewe.
					Rack/Pos		241-0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
				Age	Department		
	Birth		· · · · · · · · · · · · · · · · · ·		Physician		
					Туре	Standard	
	comm	mple rents					
-	عدد د			Range			
RBC	4.63		10ε/μL	3.80 - 6.00			Recommended actions Slide review
HGB			g/dL	11.5 - 17.0			Afarms
HCT	39.6	:	%	35.0 - 52.0	1 1	RBC	Control failed WBC
MCV	85.4		µm³	76.0 - 100.0			Background Noise
MCH	27.9		Pg	27.0 - 34.0			LYM Interference
MCHC	32.6		g/dL	32.0 - 35.0			Abnormal Differentiation
RDW-CV	15.5	4.2	%	11.0 - 17.0			Susp. Pathologies PLT aggregate or NRBC?
KDM-2D	50.4	h	hw ₃	37.0 - 49.0	50 198 159		1 aggregate of MKSC 3
PLT	267			Range			
PCT	0.31	*	103/山	150 - 400		;PLT	
MPV	11.6	*	%	0.15 - 0.40			
PDW	21.6	h*	μm³	8.0 - 11.0			
	-	*	μm³	11.0 - 22.0			De in date deleté élégéese d'élégée
P-LCR	45.7		103/HF	44 - 140			âyar Bona Hêbûrî
FILLER	43.7		%	18.0 - 50.0	2 10 20	30	
			un I grand Turker	Range			
WBC	9.53	*	103/µL 3	50 - 10.00		DIF	
	#		Range	% Range			
NEU	6.27	*	1.60 - 7.00	66.1 * 40.0 - 73.0			
LYM	2.25	*	1.00 - 3.00	23.8 * 15.0 - 45.0			
MON	0.57	*	0.20 - 0.80	6.1 * 4.0-12.0			
EOS	0.32	*	0.00 - 0.50	3.4 * 0.5 - 7.0			
	0.06	*	0.00 - 0.15	0.6 * 0.0 - 2.0			
LIC	0.06	*	0.00 - 0.10	0.7 * 0.0 - 1.0			

				Slide Re	view		
Neutrophil				Myelobiast			
ymphocyte			ŧ.:	Promyelocyte		ocytosis	
Мопосу tе				Myelocyte	and carriers and affile by ending the billion	ochromia	
Eosinophil					Polyc	chromasia	
Basophil				Metamyelocyte	Polki	locytosis	
typical Lymp	hocuta			Blast	Micro	cytosis	
ther				Target Cell	Macr	ocytosis	
1915 -5 5				Sickle Cell	that are the second of the second		The second section of the second section is a first second

)3/05/2023 04:16:20 PM

Reviewed on

Printed by : LUPIN

Sickle Cell

S/N 106YAXH03393

Platelet Clumps

Signature :



				Results
	Run E	Pate 03/05/202	3 04:17:12 PM	Operator LUPIN
	Last Na	eme		그 목사 그 그 사이에 다른 사람은 사람들이 그게 됐다. 그런 물리는 그리고 되었다면 되었다.
	First Na			Sample ID DS VALI DAY-6
	Gen	der	Age	Rack/Pos
	Patien	t ID	Age	Department
	Birth D			Physician
				Type Standard
	Sam comme			
70.00	E 20	e and the second	Range	Recommended actions
RBC	5.30	106/µL	3.80 - 6.00	Slide review
HGB	14.4	g/dL	11.5 - 17.0	Alarms
НСТ	44.6	%	35.0 - 52.0	Control falled
MCV	84.1	μm³	76.0 - 100.0	HBC WBC
MCH	27.1	pg	27.0 - 34.0	Abnormal Differentiation
MCHC	32.2	g/dL	32.0 - 35.0	- P ### ## 14 M 24 A / P A A A A A A A A A
DW-CA	15.3	%	11.0 - 17.0	RBC PLT Interference
DW-5D	49.6	h µm³	37.0 - 49.0	Susp. Pathologies se 121 150 Macroplatelets
			Range	PLT aggregate or NRBC ?
PLT	208	* 10³/µL	150 - 400	
PCT	0.28	* %	0.15 - 0.40	
MPV		H∗ µm³	8.0 - 11.0	
PDW		H* μm³	11.0 - 22.0	[44명 : 14] [41] [41] 전 [22명 (44명 - 44명
P-LCC	121	10³/µL	44 - 140	
P-LCR	58.0	7 %	18.0 - 50.0	2: 10 20 30
da.		1.4	ing the parameter of the terror of	
			Range	
WBC	4.32	* 10³/µL	3.50 - 10.00	
		r.	172.	
	#	Range	%	Range
	and the same of th	* 1.60 - 7.0	39.4 1* 40	.0 - 73.0
	and the second	* 1.00 - 3.00	50.7 h* 15	.0 - 45.0
	THE RESERVE AND ADDRESS OF THE PERSON NAMED IN	* 0.20 - 0.80		0-12,0
		k 0.00 - 0.50	2.7 * 0.	5-7.0
1.0		k 0.00 - 0.15		0-2.0
LIC	0.02	k 0.00 - 0.10		0-1.0

Slide Review

Neutrophil	Myeloblast Anisocytosis
Lymphocyte	
Monocyte	
Eosinophii	- Sycan Official
Basophil	Disas
Atypical Lymphocyte	Microcytosis
Other	Macrocytosis
	Sickle Cell Platelet Clumps
Reviewed on	bySignature:

03/05/2023 04:33:45 PM

Printed by : LUPIN

5/N 106YAXH03393



HORIBA India Private Limited

246, Okhla Industrial Estate Phase-III, New Delhi 110020, India

Tel :+91 (11) 4646 5000 / 4669 5001 Fax :+91 (11) 4646 5020 https://www.horiba.com CIN :U73100DL2006PTC153232

14th, April 2021

To Whom so ever it may concern Subject: Proficiency Testing

Dear Sir / Madam,

We would like to inform that performance of HORIBA Yumizen 500/550 has been successfully validated on different Proficiency testing programs, including Bio-Rad (EQAS) & Randox (RIQAS) programs. There are large number of users across the globe including India using Bio-Rad (EQAS) & Randox (RIQAS) successfully.

However, we had received few concerns specially with non-correlation of WBC counts from customers enrolled with AIIMS proficiency testing. In Initial investigation we had observed that there are limited Peer group data for HORIBA Yumizen 500/550 which might be reasons for difference in correlation. However, our technical team is working on the same and any development would be shared shortly.

Thank you for your continued trust in HORIBA Medical products & let us know should you need any additional information.

